PUBLISHER: DelveInsight | PRODUCT CODE: 1159566
PUBLISHER: DelveInsight | PRODUCT CODE: 1159566
DelveInsight's , "Postherpetic Neuralgia - Pipeline Insight, 2022," report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Postherpetic Neuralgia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Postherpetic Neuralgia Understanding
Postherpetic Neuralgia: Overview
Post-herpetic neuralgia (PHN) is defined as a chronic neuropathic pain that persists for three or more months following acute Herpes zoster (shingles) infection. It is a severe painful secondary phase, which may develop three to six months after the resolution of initial phase of Herpes zoster (HZ) infection. Pain has a dermatomal distribution and is confined to same dermatome as the rash. Herpes zoster infection results from activation of the varicella zoster virus (VZV) which remains latent in dorsal root ganglia since the first infection of chickenpox (varicella). Pain frequently precedes Herpes zoster infection (pre-herpetic neuralgia), and outlasts the herpetic rash by some weeks. It is more common in older individuals (develops in up to 75% of patients over 70 years of age) and is less common in individuals younger than fifty years of age. Post-herpetic neuralgia subsides eventually on its own. However, it may make patients suffer for years and may leave a band of anaesthetic skin. It may lead to muscle weakness as well, if it affects major motor nerve. Post-herpetic neuralgia is associated with persistent and, very often, refractory neuropathic pain. The neuralgia is excruciating with superimposed lancinating paresthesias. Pain may be constant or intermittent, aggravated by minor stimulus (allodynia) such as heat or touch, and is worse at night. The agony of pain leads to insomnia, anorexia, and changes in mood (severe depression).
"Postherpetic Neuralgia - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Postherpetic Neuralgia pipeline landscape is provided which includes the disease overview and Postherpetic Neuralgia treatment guidelines. The assessment part of the report embraces, in depth Postherpetic Neuralgia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Postherpetic Neuralgia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Postherpetic Neuralgia Emerging Drugs Chapters
This segment of the Postherpetic Neuralgia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Postherpetic Neuralgia Emerging Drugs
HSK16149 is being developed by Haisco Pharmaceutical Group to treat Postherpetic Neuralgia. The company is currently conducting a multicenter, randomized, double-blind, placebo-controlled, 12-week, Phase III study to evaluate the efficacy and safety of HSK16149 capsules in chinease patients with Postherpetic Neuralgia.
LX9211 is an orally-delivered small molecule compound that we are developing as a treatment for neuropathic pain. Scientists identified the target of LX9211, adapter-associated kinase 1, or AAK1, in a target discovery efforts based on their discovery that mice lacking AAK1 exhibited increased resistance to induced neuropathic pain in preclinical models. LX9211 and another development candidate were discovered by scientists working within Lexicon's drug discovery alliance with Bristol-Myers Squibb from which Lexicon hold exclusive development and commercialization rights. Currently, it is in Phase II stage of clinical trial evaluation to treat Postherpetic Neuralgia.
Further product details are provided in the report……..
Postherpetic Neuralgia: Therapeutic Assessment
This segment of the report provides insights about the different Postherpetic Neuralgia drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 12+ key companies which are developing the therapies for Postherpetic Neuralgia. The companies which have their Postherpetic Neuralgia drug candidates in the most advanced stage, i.e. phase III include, Haisco Pharmaceutical Group.
DelveInsight's report covers around 12+ products under different phases of clinical development like
Postherpetic Neuralgia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Postherpetic Neuralgia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Postherpetic Neuralgia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Postherpetic Neuralgia drugs.
Key Questions
Current Treatment Scenario and Emerging Therapies:
Key Players
Key Products
Introduction
Executive Summary
Postherpetic Neuralgia: Overview
Pipeline Therapeutics
Therapeutic Assessment
Postherpetic Neuralgia - DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
HSK16149: Haisco Pharmaceutical Group
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
LX9211: Lexicon Pharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Drug name: Company name
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
AAT 730: Oxford Cannabinoid Technologies
Drug profiles in the detailed report…..
Inactive Products
Postherpetic Neuralgia Key Companies
Postherpetic Neuralgia Key Products
Postherpetic Neuralgia- Unmet Needs
Postherpetic Neuralgia- Market Drivers and Barriers
Postherpetic Neuralgia- Future Perspectives and Conclusion
Postherpetic Neuralgia Analyst Views
Postherpetic Neuralgia Key Companies
Appendix